Yixiao Wang

Ms. Yixiao Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Science Advances
Verified
Journal Article
Open access
YWYixiao Wang
Yixiao Wang
ASAaron Snell
Aaron Snell
FDFrank M. Dyka
Frank M. Dyka
ECElizabeth R. Colvin
Elizabeth R. Colvin
CICristhian J. Ildefonso
Cristhian J. Ildefonso
ELEkaterina Lobanova
Ekaterina Lobanova
Proteasomes are the central proteolytic machines that are critical for breaking down most of the damaged and abnormal proteins in human cells. Although universally applicable drugs are not yet available, the stimulation of proteasomal activity is being analyzed as a proof-of-principle strategy to increase cellular resistance to a broad range of proteotoxic stressors. These approaches have included the stimulation of proteasomes through the overexpression of individual proteasome subunits, phosphorylation, or conformational changes induced by small molecules or peptides. In contrast to these approaches, we evaluated a transcription-driven increase in the total proteasome pool to enhance the proteolytic capacity of degenerating retinal neurons. We show that overexpression of nuclear factor erythroid-2-like 1 (Nfe2l1) transcription factor stimulated proteasome biogenesis and activity, improved the clearance of the ubiquitin-proteasomal reporter, and delayed photoreceptor neuron loss in a preclinical mouse model of human blindness caused by misfolded proteins. The findings highlight Nfe2l1 as an emerging therapeutic target to treat neurodegenerative diseases linked to protein misfolding.

11 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YWYixiao Wang
Yixiao Wang
CPClaudio Punzo
Claudio Punzo
JAJohn D. Ash
John D. Ash
ELEkaterina Lobanova
Ekaterina Lobanova
Significance: Studies in multiple experimental systems have demonstrated that an increase in proteolytic capacity of post-mitotic cells improves cellular resistance to a variety of stressors, delays cellular aging and senescence. Therefore, approaches to increase the ability of cells to degrade misfolded proteins could potentially be applied to the treatment of a broad spectrum of human disorders. An example would be retinal degenerations, which cause irreversible loss of vision and are linked to impaired protein degradation. This study suggests that chronic activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway in degenerating photoreceptor neurons could stimulate the degradation of ubiquitinated proteins and enhance proteasomal activity through phosphorylation.

23 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
ESEmily Sechrest
Emily Sechrest
XMXiaojie Ma
Xiaojie Ma
MCMarion E. Cahill
Marion E. Cahill
RBRobert J. Barbera
Robert J. Barbera
YWYixiao Wang
Yixiao Wang
Wen-Tao DengWen-Tao Deng
Wen-Tao Deng
An arginine to cysteine substitution at amino acid position 203 (C203R) is the most common missense mutation in human cone opsin. Linked to color blindness and blue cone monochromacy (BCM), C203 is involved in a crucial disulfide bond required for proper folding. It has previously been postulated that expression of mutant C203R cone opsin exerts a toxic effect on cone photoreceptors, similar to some well-characterized missense mutations in rhodopsin that lead to protein misfolding. In this study, we generated and characterized a BCM mouse model carrying the equivalent C203R mutation ( Opn1mw C198R Opn1sw –/– ) to investigate the disease mechanism and develop a gene therapy approach for this disorder. Untreated Opn1mw C198R Opn1sw –/– cones phenocopied affected cones in human patients with the equivalent mutation, exhibiting shortened or absent cone outer segments and loss of function. We determined that gene augmentation targeting cones specifically yielded robust rescue of cone function and structure when Opn1mw C198R Opn1sw –/– mice were treated at early ages. Importantly, treated cones displayed elaborated outer segments and replenished expression of crucial cone phototransduction proteins. Interestingly, we were unable to detect OPN1MW C198R mutant opsin at any age. We believe this is the first proof-of-concept study exploring the efficacy of gene therapy in BCM associated with a C203R mutation.